By stimulating invasion ability, disrupting E-cadherin-mediated cell adhesion, and inducing the recycling of β-catenin, the high expression of ARF6 promotes the development of breast cancer, renal cell carcinoma, lung adenocarcinoma and colorectal cancer [40–42]. Here, CDH1 is linked to breast carcinoma.